The main purpose of this study in healthy participants is to find out whether the traditional ambulatory blood pressure monitor (ABPM) and newer wearable devices (EmbracePlus smartwatch device, Biobeat chest patch device, and Aktiia wrist device) will accurately pick up changes in blood pressure caused by 2 different medications (propranolol and pseudoephedrine). The study will last about 29 days excluding the screening period of 28 days.

开始日期2023-01-31

申办/合作机构

Eli Lilly & Co.

NCT05697328 / RecruitingN/AIIT

Pseudoephedrine Prophylaxis for Prevention of Middle Ear Barotrauma in Hyperbaric Oxygen Therapy

The purpose of this research is to study whether the use of pseudoephedrine can help prevent middle ear trauma during HBOT. Pseudoephedrine is an approved drug that is used for temporary relief of nasal or sinus pain and pressure.

开始日期2023-01-31

申办/合作机构

John Muir Health

ACTRN12622000542796 / Completed临床2期

Exploring the activity of pseudoephedrine in treating retrograde ejaculation following retroperitoneal lymph node dissection (RPLND) in survivors of testicular cancer - Part B

开始日期2022-09-06

申办/合作机构

Peter MacCallum Cancer Institute

100 项与硫酸伪麻黄碱相关的临床结果

登录后查看更多信息

100 项与硫酸伪麻黄碱相关的转化医学

登录后查看更多信息

100 项与硫酸伪麻黄碱相关的专利（医药）

登录后查看更多信息

1,250

项与硫酸伪麻黄碱相关的文献（医药）

2024-06-01·Journal of Ethnopharmacology

Mahuang Fuzi Xixin decoction alleviates allergic rhinitis by inhibiting NLRP3/Caspase-1/GSDMD-N-mediated pyroptosis

Article

作者: Tan, Xiaomei ; Wei, Xiaohan ; Liu, Changshun ; Ding, Mengze

ETHNOPHARMACOLOGICAL RELEVANCEAllergic rhinitis (AR) is a prevalent nasal inflammatory disorder, and pyroptosis plays a crucial role in aggravating AR. Current medications for AR treatment still have deficiencies, and finding new agents is of great interest. Mahuang Fuzi Xixin decoction (MFXD), an ancient Chinese medicine, is now commonly used to treat AR, which has anti-inflammatory and immunomodulatory effects, but its underlying mechanism is unknown.AIM OF THIS STUDYThis study aims to evaluate the effects of MFXD on AR and explore its potential mechanisms in view of the regulatory effect on pyroptosis.METHODSMFXD, Mahuang, Fuzi, and Xixin water extracts were analyzed using ultra high performance liquid chromatography-Orbitrap-high-resolution accurate mass spectrometry. In in vivo study, the effects of MFXD on AR treatment were evaluated in an ovalbumin-induced mouse model. Mice were administered saline (control and model groups), MFXD (1.375, 2.75 g/kg), and dexamethasone (2.5 mg/kg) for 13 days. AR symptoms were evaluated by blinded observers. Immunoglobulin E (IgE) and histamine levels were measured using enzyme-linked immunosorbent assays. Expression of pyroptosis-related proteins (NLRP3, ASC, Caspase-1 p10/p20, GSDMD-N and IL-1β) in AR mouse nasal mucosa were estimated by immunohistochemistry. In in vivtro study, the effects of MFXD on pyroptosis were assessed in human nasal epithelial cells (HNEpCs) stimulated with lipopolysaccharide (LPS) and adenosine triphosphate (ATP), and incubated with MFXD (12.5, 25, and 50 μg/mL). Pyroptosis-related protein expression was measured by western blotting.RESULTSThirty-three compounds in MFXD were identified, including ephedrine, pseudoephedrine, higenamine, aconine, aconitine, benzoylmesaconitine, benzoylhypaconine and hypaconitine. In the in vivo study, oral taken of MFXD/dexamethasone significantly ameliorated AR symptoms, reduced swelling of the nasal mucosa, and decreased the levels of IgE and histamine in AR mice serum. MFXD/dexamethasone attenuated histopathological changes and reduced the expression of pyroptosis-related proteins in nasal mucosa, indicating the inhibitory effect on nasal epithelial pyroptosis. In the in vitro study, MFXD (50 μg/mL) significantly alleviated cytotoxicity, protected cells from swelling and rupture, and downregulated the expression of pyroptosis-related proteins in LPS/ATP-induced HNEpCs.CONCLUSIONMFXD suppressed nasal epithelial pyroptosis by inhibiting the NLRP3/Caspase-1/GSDMD-N signaling pathway, which alleviates AR. Our results offer valuable insights into potential AR therapies and provide evidence for the clinical utilization of MFXD to treat AR.

2024-05-01·Journal of Infection and Public Health

Changes in pharmacist’s recommendations of over-the-counter treatments for the common cold during the COVID-19 pandemic

Article

作者: Kopa-Stojak, Paulina Natalia ; Pietrusiewicz, Malgorzata ; Pawliczak, Rafal

BACKGROUNDThe common cold is one of the most frequently occurring illnesses worldwide. The aim of this study was to determine which OTC anti-common cold medications were most often recommended by pharmacists and if the COVID-19 pandemic affected such recommendations.METHODSNon-interventional, observational research trial using a self-developed questionnaire to collect data on pharmacists' recommendations for anti-common cold OTC treatment. The data were collected during the COVID-19 pandemic (December 2021-February 2022) in four large community network pharmacies in Lodz (Poland) and then compared with an analogue period of time before the pandemic (December 2019-February 2020).RESULTSDuring COVID-19 pandemic there was a significant (p < 0.05) reduction in paracetamol, acetylsalicylic acid, metamizole magnesium, inosines, alpha-mimetics, mucolytics, homeopathics, and sore throat products and an increase in other tablets/capsules and add-on product recommendations. There was a significant relationship (p < 0.05, OR > 1) between the recommended frequency of paracetamol, inosines, sore throat products (each symptom), metamizole magnesium (headache, fever), acetylsalicylic acid (headache, fever, fatigue), NSAIDs, alpha-mimetics (headache, rhinorrhea), pseudoephedrine (rhinorrhea), homeopathics (headache), herbal products (fatigue), antihistamines (rhinorrhea, cough), and mucolytics (headache, fever, cough).CONCLUSIONSFavorable prices (before COVID-19 pandemic) and reports on common NSAIDs side effects (beginning of the pandemic) led to high sale of paracetamol. Increased awareness of clinical effectiveness of some medications or their reduced availability influenced their limited recommendations.

2024-03-05·JAMA

Trends in Phenylephrine and Pseudoephedrine Sales in the US

Article

作者: Gellad, Walid F ; Suda, Katie J ; Tadrous, Mina ; Anderson, Timothy S

This study examines purchasing patterns regarding oral decongestants, concerns about their efficacy, and the need for timelier postmarket evaluation.

项与硫酸伪麻黄碱相关的新闻（医药）

2024-03-28

·PRNewswire

U.S. News Reveals the 2024 Best OTC Medicine & Health Products

2024 edition includes 30+ new product categories evaluated, new dermatologist expert panel reviewers. WASHINGTON, March 28, 2024 /PRNewswire/ -- U.S. News & World Report, the global authority in health care rankings and consumer advice, today published the second annual Best OTC Medicine & Health Products. The latest edition of the rankings features 132 categories, with 33 brand new over-the-counter product categories included this year. The brands with the most No. 1 products among the 2024 rankings are Nature Made, followed by CeraVe and Neutrogena; the companies with the most No. 1 products are Kenvue Inc., followed by Haleon plc and Pharmavite LLC. "With hundreds of thousands of over-the-counter health products on the market in the U.S., the U.S. News annual Best OTC Medicine & Health Products rankings help consumers choose the best OTC products for themselves and their families," said Sumita Singh, general manager of Health at U.S. News. "Continuing our commitment to offer consumers trusted, data-backed ratings and rankings to help with their health care decisions, the 2024 evaluation features statistically 'best' brands evaluated by hundreds of pharmacists and dermatologists." In partnership with global market research firm The Harris Poll, U.S. News surveyed 354 pharmacists and 122 dermatologists practicing in the United States regarding 132 product categories such as adult and children's cough suppressants, men's and women's multivitamins, fish oil/omega-3 supplements, baby formula, face washes and cleansers, and retinol creams and serums. This was the first year that dermatologists were included in the survey, which was administered online in February 2024. To determine the rankings, panelists selected their top three recommended brands within each product category assigned to them. The brands that were highly ranked most often were ranked No. 1 for the corresponding product categories. U.S. News awarded the designations of Best OTC Medicine & Health Products only to those brands that satisfy U.S. News' statistical assessment of performance on the survey. Based on U.S. News' analysis, some product categories were awarded more than one winner. Some popular 2024 product category winners, ranked No. 1, evaluated by pharmacists include: Children's Cough Medicines: Children's Delsym Cough Drops: Halls Cough Suppressants: Delsym Decongestants, Oral: Sudafed (Pseudoephedrine) Diarrhea Medicines and Treatments: Imodium Eye Vitamins: Bausch + Lomb Ocuvite Fish Oil/Omega-3 Supplements: Nature Made Laxatives: MiraLAX Multivitamins for Men: Centrum Multivitamins for Women: One A Day Nausea Remedies: Dramamine Nausea Saline Nasal Sprays: Ayr Sore Throat Sprays: Chloraseptic Some popular 2024 product category winners, ranked No. 1, evaluated by dermatologists include: Eye Cream for Wrinkles: La Roche-Posay Face Moisturizers: CeraVe Face Washes and Cleansers: CeraVe Hand Creams: Neutrogena Moisturizers With SPF: CeraVe Night Creams: CeraVe Retinol Creams and Serums: Neutrogena Sunscreen for Face: EltaMD Vitamin C Serum: La Roche-Posay Vitamins for Hair Growth: Nutrafol Wrinkle Creams: Neutrogena Those looking to choose a health product that's right for them or their child should consult a medical professional as part of their decision-making process. For the full rankings, visit U.S. News' 2024 Best OTC Medicine & Health Products. Explore more of the 2024 product rankings using #BestOTCProducts on Facebook, Instagram, TikTok and X (formerly Twitter). About U.S. News & World Report U.S. News & World Report is the global leader in quality rankings that empower consumers, business leaders and policy officials to make better, more informed decisions about important issues affecting their lives and communities. A multifaceted digital media company with Education, Health, Money, Travel, Cars, News, Real Estate, Careers and 360 Reviews platforms, U.S. News provides rankings, independent reporting, data journalism, consumer advice and U.S. News Live events. More than 40 million people visit USNews.com each month for research and guidance. Founded in 1933, U.S. News is headquartered in Washington, D.C. About The Harris Poll The Harris Poll is a global consulting and market research firm that delivers proven intelligence for transformational times. Responsible for one of the longest-running surveys in the United States, Harris Poll provides unique context and social insights based on having analyzed public opinion, motivations, and social sentiment since 1963. It works with clients in three primary areas: building modern corporate reputation, crafting brand strategy and performance tracking, and data-driven thought leadership. It also delivers industry-leading healthcare insights expertise, specializing in research with patients, caregivers, nurses, physicians, specialists (across over 50 therapeutic areas) payers, hospital decision makers, policy makers, and pharmacists. Its mission is to provide insights and guidance to help leaders make the best decisions possible. To learn more, please visit . SOURCE U.S. News & World Report, L.P.

2023-09-24

·赛柏蓝

FDA认定一感冒成分无效？这些药品或受影响

近日，FDA召开非处方药咨询委员会会议，专门讨论口服去氧肾上腺素作为非处方咳嗽和感冒产品活性成分的有效性。委员会讨论了口服去氧肾上腺素有效性的新数据，最终得出一致结论：当前的科学数据，并不支持口服去氧肾上腺素作为鼻减充血剂的有效性（投票结果16：0）。虽然FDA没有明确说明剂量，但大量文献指出，口服去氧肾上腺素（40毫克）无效【1】。这意味着Sudafed PE这样的名牌药物(Sudafed PE约占去氧肾上腺素市场的五分之一)，可能并没有广告中宣传的减轻鼻塞的效果。01去氧肾上腺素的「生前身后名」去氧肾上腺素是一种α-1肾上腺素能受体激动剂，通过刺激鼻道血管内壁平滑肌上的受体，缩小鼻道中的血管，从而减少肿胀和充血，通常用于缓解由普通感冒、过敏或鼻窦炎等疾病引起的鼻塞和不适。尽管咨询委员会对口服去氧肾上腺素的有效性提出了否定，但其是否等同于“无效”还需由FDA正式认定。FDA声明中涉及一项关键内容，即咨询委员会的建议仅涉及“口服”去氧肾上腺素（片剂或胶囊），而不针对鼻喷雾剂。FDA还表示，含有去氧肾上腺素的药物，对于散瞳和手术期间使用同样有效，并不受到此次决定的影响。对此，佛罗里达大学药学博士Leslie Hendeles表示，“只有口服途径是无效的，因为99%的母体药物在肠道和肝首过代谢时就失活了”。Hendeles领导了佛罗里达大学2015年提交的公民请愿书，要求从OTC鼻减充血剂产品的OTC monograph中删除口服去氧肾上腺素。通常来说，当一种OTC药物从OTC monograph中删除，可能会对消费者、制造商和监管环境产生重大影响。例如，若去氧肾上腺素最终遭到FDA除名，伪麻黄碱的需求量可能会激增，以填补去氧肾上腺素的空缺。而后续的监管部门药物管控、患者药物获取等都会受到影响。笔者在药智数据库查询发现，国内上市药品中，含有去氧肾上腺素的口服非处方药包含柳酚咖敏片等品种，其去氧肾上腺素的剂量大多在2.5mg-5mg之间。除了化学减充血剂药物之外，桉树油、薄荷醇、生姜、大蒜、蜂蜜等自然疗法也具有缓解鼻塞的潜力。不知道这对于拥有悠久草本入药历史的中国来说，是否意味着机遇？02哪些品种将受影响？FDA官方网站上发布的声明称，有些产品只含有去氧肾上腺素，而某些产品则含有去氧肾上腺素和另一种活性成分（例如对乙酰氨基酚或布洛芬），可针对鼻塞之外的其它症状，例如头痛或肌肉酸痛等，这些产品中的去氧肾上腺素的存在，并不会影响其他活性成分治疗这些症状。FDA表示，含有去氧肾上腺素成分的产品大约有250种，其在2022年的销售额约为18亿美元。包括Tylenol、NyQuil、Mucinex、Theraflu和Benadryl等知名感冒和流感产品。如果FDA遵循咨询小组的建议，强生、拜耳和其他制药商可能会被要求从商店货架上撤下含有去氧肾上腺素的口服药物。这可能会迫使消费者转而使用非处方药，或者使用含有去氧肾上腺素的鼻喷雾剂和滴剂。美国消费者保健产品协会(CHPA，The Consumer Healthcare Products Association)于9月12日发表声明，对FDA咨询委员会的调查结果表示失望，并敦促FDA将去氧肾上腺素继续留在市场上。CHPA表示，撤销去氧肾上腺素的非处方药资格将对医药市场造成明显的破坏性。除名去氧肾上腺素的决定将增加消费者负担，原本可以轻松从药店购买到的OTC可能会无迹可寻。患者需要寻求替代疗法，或者向医生寻求处方，这将导致就诊次数和医疗费用增加。CHPA还认为，除名去氧肾上腺素，无论对医药成本、患者依从性、供应链，都将造成意义深远的影响。FDA数据显示，去年美国零售店销售了2.42亿瓶含有去氧肾上腺素的药物，比2021年增长了30%。这些产品去年的销售额为18亿美元。03剥夺非处方药资格后，巨大空缺谁来填补？如果去氧肾上腺素最终被FDA剥夺了非处方药资格，其留下的巨大空缺将由谁来填补？伪麻黄碱（Pseudo-ephedrine）算得上一号。伪麻黄素是一种去除鼻塞和鼻窦充血的药物，有效收缩鼻腔和鼻窦中的血管，从而减轻鼻塞和流感症状，通常用于治疗感冒、过敏性鼻炎和鼻窦炎等呼吸道疾病的症状。实际上，伪麻黄碱因为可以当作合成甲基苯丙胺的原料，甲基苯丙胺就是俗称的冰毒。受甲基苯丙胺影响，许多国家对伪麻黄素的销售和购买都有限制，并要求购买者提供身份信息，以确保合法使用。含有伪麻黄碱的产品仍然可以作为非处方药购买，但获取伪麻黄素药物不可能像去氧肾上腺素那样轻而易举。相比于去氧肾上腺素2022年2.42亿瓶和18亿美元的销售额，同期伪麻黄素的销量估计为5100万件，销售额为5.42亿美元。除了去氧肾上腺素和伪麻黄素之外，获批的nasal decongestant还包括：Levomethamphetamine（左旋甲基苯丙胺，甲基苯丙胺的L-对映体，亦称左旋甲基安非他命）:一种拟交感神经血管收缩剂，用于美国的一些非处方(OTC)鼻减充血剂。不同于右旋甲基苯丙胺，它在低剂量没有造成欣快或成瘾的特性。Oxymetazoline（羟甲唑啉）：一种α-1A肾上腺素受体激动剂，可用于治疗鼻充血、眼睛过敏反应以及与红斑痤疮相关的面部红斑。羟甲唑啉可作为鼻减充血剂用于非处方鼻用产品中。羟甲唑啉具有良好的外周血管收缩作用，直接激动血管α-1受体，引起鼻腔黏膜血管收缩，从而减轻炎症所致的充血和水肿。它起效迅速，在几分钟内即可发生作用，可维持数小时，能有效地解除鼻充血。Ephedrine（麻黄碱）：一种α和β肾上腺素能激动剂，用于治疗麻醉下低血压、过敏性疾病、支气管哮喘和鼻塞。Propylhexedrine（丙己定）：一种α-肾上腺素能激动剂，常用于鼻减充血吸入剂。它用于暂时缓解感冒、过敏性鼻炎或过敏引起的鼻塞。Xylometazoline（丁苄唑啉，亦称赛洛唑啉）：一种直接作用的α-肾上腺素能激动剂，用于对过敏或感冒引起的鼻充血和轻微炎症的对症治疗。不建议使用超过七天。同样，不建议三个月以下的婴儿使用，有的说法甚至建议不要在6岁以下儿童使用。虽然当前的科学数据并不支持口服去氧肾上腺素作为鼻减充血剂的有效性，但相关药品市场受到的直接影响还要等待FDA下一步动作。END作者 | 骎丹翼来源 | 药智网赛柏蓝药械交流46群扫描下方二维码进入赛柏蓝药械交流群医药代表转型之患者招募扫描下方二维码进入赛柏蓝患者招募群

2023-09-22

·药智网

FDA认定这一感冒成分无效，这些药品或将受影响

近日，FDA召开了非处方药咨询委员会会议，专门讨论口服去氧肾上腺素作为非处方咳嗽和感冒产品活性成分的有效性。委员会讨论了口服去氧肾上腺素有效性的新数据，最终得出一致结论：当前的科学数据，并不支持口服去氧肾上腺素作为鼻减充血剂的有效性（投票结果16：0）。虽然FDA没有明确说明剂量，但大量文献指出，口服去氧肾上腺素（40毫克）无效【1】。这意味着Sudafed PE这样的名牌药物(Sudafed PE约占去氧肾上腺素市场的五分之一)，可能并没有像广告宣传的那样发挥减轻鼻塞的效果。FDA认定这一感冒成分无效，哪些药品受影响？01去氧肾上腺素的「生前身后名」去氧肾上腺素是一种α-1肾上腺素能受体激动剂。它通过刺激鼻道血管内壁平滑肌上的受体，导致血管收缩（变窄）。去氧肾上腺素通常用于缓解由普通感冒、过敏或鼻窦炎等疾病引起的鼻塞和不适。去氧肾上腺素的作用是缩小鼻道中的血管，从而减少肿胀和充血，使呼吸更容易。尽管对于口服去氧肾上腺素的有效性提出了否定，但这是否等同于”无效“，最终还需要FDA拍板定夺。咨询委员会只负责向FDA提供独立的意见和建议，但最终的决定权在FDA手中。笔者在药智数据库查询发现，国内上市药品中，含有去氧肾上腺素的口服非处方药，包含柳酚咖敏片等品种，其去氧肾上腺素的剂量大多在2.5mg-5mg之间。尽管FDA咨询委员会给出了“无法证明有效性”的结论，但仍然存在很多不确定因素：FDA是否会正式将去氧肾上腺素除名？下架的药物，仅限于去氧肾上腺素作为唯一有效物质的药物，还是牵连所有包含去氧肾上腺素的复方制剂？美国以外的监管机构会做出如何反应？通常来说，当一种OTC药物从OTC monograph中删除，可能会对消费者、制造商和监管环境产生重大影响。这些影响可能会因具体药物、除名原因以及可用替代品而异。如果去氧肾上腺素最终遭到FDA除名的话，可以想象，伪麻黄碱的需求量可能会出现激增，以填补去氧肾上腺素身后留下的巨大空缺。而如何在确保伪麻黄碱这种管控药物不流向甲基苯丙胺的方向，将成为美国政府需要重点关心的事情。对于患者来说，如何更容易地获得伪麻黄碱这种所谓的behind-the-counter药物（柜台后药物），也是一件关乎顺利过渡的事情。除了化学减充血剂药物之外，桉树油、薄荷醇、生姜、大蒜、蜂蜜等自然疗法也具有缓解鼻塞的潜力。不知道这对于拥有悠久草本入药历史的中国来说，是否意味着一个机遇？FDA的声明中还涉及到一项关键内容，即咨询委员会的建议仅涉及“口服”去氧肾上腺素（片剂或胶囊），而不针对鼻喷雾剂。含去氧肾上腺素的鼻喷雾剂不会受到任何连带影响。对此，佛罗里达大学药学博士Leslie Hendeles表示，“只有口服途径是无效的，因为99%的母体药物在肠道和肝首过代谢时就失活了”。Hendeles领导了佛罗里达大学2015年提交的公民请愿书，要求从OTC鼻减充血剂产品的OTC monograph中删除口服去氧肾上腺素。FDA还表示，含有去氧肾上腺素的药物，对于散瞳和手术期间使用同样有效，并不受到此次决定的影响。02除名去氧肾上腺素，哪些品种将受影响？在FDA官方网站上发布的声明称，有些产品仅含有去氧肾上腺素，而某些产品则含有去氧肾上腺素和另一种活性成分（例如对乙酰氨基酚或布洛芬），可针对鼻塞之外的其它症状，例如头痛或肌肉酸痛等，这些产品中的去氧肾上腺素的存在，并不会影响其他活性成分治疗这些症状。但在FDA正式将去氧肾上腺素认定对缓解鼻塞无效，并将其从OTC monograph中除名之后，含有去氧肾上腺素成分的复方药物的命运目前仍待观察。FDA表示，含有去氧肾上腺素成分的产品大约有250种，其在2022年的销售额约为18亿美元。受到去氧肾上腺素牵连的知名药物包括Tylenol,NyQuil,Mucinex,Theraflu和Benadryl等感冒和流感产品。如果FDA最终做出下架的决定，将有250种以上的产品受到影响。如果FDA遵循咨询小组的建议，强生、拜耳和其他制药商可能会被要求从商店货架上撤下含有去氧肾上腺素的口服药物。这可能会迫使消费者转而使用非处方药，或者使用含有去氧肾上腺素的鼻喷雾剂和滴剂。图片来源：SUDAFED PE、DrugSupplyStore.com、Walmart、amazon、HEB美国消费者保健产品协会(CHPA，The Consumer Healthcare Products Association)于9月12日发表声明，对FDA咨询委员会的调查结果表示失望，并敦促FDA将去氧肾上腺素继续留在市场上。CHPA表示，撤销去氧肾上腺素的非处方药资格将对医药市场造成明显的破坏性。除名去氧肾上腺素的决定将增加消费者负担，原本可以轻松从药店购买到的OTC可能会无迹可寻。患者需要寻求替代疗法，或者向医生寻求处方，这将导致就诊次数和医疗费用增加。CHPA还认为，除名去氧肾上腺素，无论对医药成本、患者依从性、供应链，都将造成意义深远的影响。FDA数据显示，去年美国零售店销售了2.42亿瓶含有去氧肾上腺素的药物，比2021年增长了30%。这些产品去年的销售额为18亿美元。03剥夺非处方药资格后，巨大空缺谁来填补？如果去氧肾上腺素最终被FDA剥夺了非处方药资格，那么它身后留下的巨大空缺将由谁来填补？伪麻黄碱(Pseudo-ephedrine)算得上一号。伪麻黄素是一种去除鼻塞和鼻窦充血的药物，通常用于治疗感冒、过敏性鼻炎和鼻窦炎等呼吸道疾病的症状。它可以有效收缩鼻腔和鼻窦中的血管，从而减轻鼻塞和流感症状。而且作为鼻减充血剂，伪麻黄碱比去氧肾上腺素更加有效。但更有效的药物却没有获得相应的市场份额，其中必有蹊跷。实际上，伪麻黄碱因为可以当作合成甲基苯丙胺的原料而无法做到洁身自好。甲基苯丙胺就是俗称的冰毒。受到甲基苯丙胺瓜田李下的影响，许多国家对伪麻黄素的销售和购买都有限制，并要求购买者提供身份信息，以确保合法使用。含有伪麻黄碱的产品仍然可以作为非处方药购买，但获取伪麻黄素药物不可能像去氧肾上腺素那样轻而易举。相比于去氧肾上腺素2022年2.42亿瓶和18亿美元的销售额，同期伪麻黄素的销量估计为5100万件，销售额为5.42亿美元。除了去氧肾上腺素和伪麻黄素之外，获批的nasal decongestant还包括：Levomethamphetamine（左旋甲基苯丙胺，甲基苯丙胺的L-对映体，亦称左旋甲基安非他命）:一种拟交感神经血管收缩剂，用于美国的一些非处方(OTC)鼻减充血剂。不同于右旋甲基苯丙胺，它在低剂量没有造成欣快或成瘾的特性。Oxymetazoline（羟甲唑啉）：一种α-1A肾上腺素受体激动剂，可用于治疗鼻充血、眼睛过敏反应以及与红斑痤疮相关的面部红斑。羟甲唑啉可作为鼻减充血剂用于非处方鼻用产品中。羟甲唑啉具有良好的外周血管收缩作用，直接激动血管α-1受体，引起鼻腔黏膜血管收缩，从而减轻炎症所致的充血和水肿。它起效迅速，在几分钟内即可发生作用，可维持数小时，能有效地解除鼻充血。Ephedrine（麻黄碱）：一种α和β肾上腺素能激动剂，用于治疗麻醉下低血压、过敏性疾病、支气管哮喘和鼻塞。Propylhexedrine（丙己定）：一种α-肾上腺素能激动剂，常用于鼻减充血吸入剂。它用于暂时缓解感冒、过敏性鼻炎或过敏引起的鼻塞。Xylometazoline（丁苄唑啉，亦称赛洛唑啉）：一种直接作用的α-肾上腺素能激动剂，用于对过敏或感冒引起的鼻充血和轻微炎症的对症治疗。不建议使用超过七天。同样，不建议三个月以下的婴儿使用，有的说法甚至建议不要在6岁以下儿童使用。04小结虽然当前的科学数据，并不支持口服去氧肾上腺素作为鼻减充血剂的有效性，但缺乏有效性支持，不等同于“无效确认”。等待FDA的下一步动作。参考来源：1.https://time.com/6314120/fda-decongestant-phenylephrine-decision/2.FDA clarifies results of recent advisory committee meeting on oral phenylephrine.FDA.14.09.2023.3.Sartain,M.FDA advisers say oral phenylephrine is not effective as a nasal decongestant.Pharmacist.com.13.09.2023.4.Dunleavy,K.It's unanimous:FDA panel says decongestant drug phenylephrine does not work.FiercePharma.13.09.2023.5.Constantino,A.K.Decongestant found in many cold,allergy medicines doesn’t actually work,FDA advisors say.CNBC.12.09.2023.6.Cerullo,M.Ineffective ingredient could make Dayquil,Sudafed and others disappear from store shelves.CBS News.12.09.2023.7.Drug Bank:Nasal Decongestant声明：本内容为作者独立观点，不代表药智网立场。如需转载，请务必注明文章作者和来源。对本文有异议或投诉，请联系maxuelian@yaozh.com。责任编辑 | 八角转载开白 | 马老师 18996384680（同微信）商务合作 | 张武龙 13368443108（同微信）阅读原文，是受欢迎的文章哦

医药出海

100 项与硫酸伪麻黄碱相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05649	硫酸伪麻黄碱	R01BA02	DB00852

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
鼻塞	中国	青海省青海湖药业有限公司	1992-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00377403 (CTgov)	临床4期	急性呼吸道感染 \| 急性鼻窦炎	172	Saline spray (0.65%)+Pseudoephedrine Sustained Action+Acetaminophen+amoxicillin+guaifenesin+Dextromethorphan hydrobromide (Intervention Arm)	遞廠窪餘簾築鏇觸簾餘(艱廠憲繭鹽構遞觸繭醖) = 鏇顧構築壓艱獵淵糧膚觸鹽製觸鹹觸艱窪簾簾 (艱顧壓網選淵顧選網築, 範膚簾製鹽淵膚廠壓廠 ~ 襯遞壓夢範憲壓糧淵製) 更多	-	2011-06-29
				Saline spray (0.65%)+Pseudoephedrine Sustained Action+Acetaminophen+guaifenesin+Dextromethorphan hydrobromide (Symptomatic Treatments Only)	遞廠窪餘簾築鏇觸簾餘(艱廠憲繭鹽構遞觸繭醖) = 願製鬱窪構鏇鏇鏇範醖觸鹽製觸鹹觸艱窪簾簾 (艱顧壓網選淵顧選網築, 鏇範蓋繭獵淵淵選窪鹹 ~ 鑰範壓壓膚遞積艱淵獵) 更多
NCT00804687 (CTgov)	临床2期	过敏性鼻炎	53	placebo (Placebo)	製膚選夢築憲願窪鹽衊(積襯願簾遞憲製蓋製積) = 顧簾遞鏇構範艱襯積齋簾構繭夢鑰醖鹹鹽蓋憲 (構齋餘製鏇積壓襯獵餘, 鑰選夢衊鬱艱積製鬱糧 ~ 糧醖淵艱憲蓋獵廠顧淵) 更多	-	2013-08-30
				JNJ-39220675 (JNJ-39220675)	製膚選夢築憲願窪鹽衊(積襯願簾遞憲製蓋製積) = 觸願鑰鹽餘艱遞齋醖觸簾構繭夢鑰醖鹹鹽蓋憲 (構齋餘製鏇積壓襯獵餘, 醖蓋餘齋糧窪鹽願顧艱 ~ 襯衊鑰糧簾鏇構鬱艱蓋) 更多
NCT01028014 (CTgov)	N/A	-	56	Pseudoephedrine (Pseudoephedrine 120mg ER Daily)	範簾餘觸構憲憲壓鹹鹹(選遞獵艱蓋獵淵齋糧鑰) = 網獵艱選窪齋簾蓋選醖淵衊範範製構鹹範顧壓 (糧鏇衊繭鏇選衊顧廠艱, 蓋積鑰衊廠壓遞夢壓窪 ~ 繭選築餘鬱願鑰獵廠製) 更多	-	2011-09-05
				Solifenacin (Solifenacin 5mg Daily)	範簾餘觸構憲憲壓鹹鹹(選遞獵艱蓋獵淵齋糧鑰) = 網製夢築範遞簾選糧構淵衊範範製構鹹範顧壓 (糧鏇衊繭鏇選衊顧廠艱, 鬱醖構齋衊蓋衊鬱繭糧 ~ 襯選蓋蓋簾夢遞鑰憲糧) 更多
AUA2018	N/A	糖尿病	-	Imipramine+pseudoephedrine	艱餘壓醖膚膚網觸餘構(製廠醖鹹網夢顧繭醖網) = 窪製壓廠築糧鬱膚網窪構鏇構鏇鹹構鏇憲鏇糧 (製淵鬱構鹽繭淵廠齋醖 ) 更多	-	2018-04-01
NCT00704496 (CTgov)	临床3期	鼻炎 \| 睡眠	34	Pseudoephedrine (Placebo)	窪積選遞醖齋蓋齋窪艱(鬱選壓繭齋廠願鹹憲範) = 鑰簾簾膚艱廠壓蓋繭糧鬱製鹹繭齋範糧鏇艱襯 (蓋齋膚鹽夢壓衊願鬱壓, 餘鬱齋築壓鹽製襯繭繭 ~ 顧積艱積鬱艱製鹹觸鹹) 更多	-	2017-10-18
				Pseudoephedrine (Pseudoephedrine)	窪積選遞醖齋蓋齋窪艱(鬱選壓繭齋廠願鹹憲範) = 衊淵醖觸願顧糧鑰鑰艱鬱製鹹繭齋範糧鏇艱襯 (蓋齋膚鹽夢壓衊願鬱壓, 築觸膚窪構鏇製鏇窪遞 ~ 積鹹積選選憲餘醖憲蓋) 更多